AAPL 229.98 0.7535% MSFT 429.03 1.0481% NVDA 137.71 3.0995% GOOGL 196.0 1.6018% GOOG 197.55 1.6151% AMZN 225.94 2.3928% META 612.77 0.2405% AVGO 237.44 3.5003% TSLA 426.5 3.0641% TSM 211.5 -1.5317% LLY 725.72 -4.208% V 319.62 0.747% JPM 259.16 1.9232% UNH 509.76 -0.1626% NVO 78.69 -5.2727% WMT 91.94 0.701% LVMUY 142.08 -1.4497% XOM 112.32 0.8983% LVMHF 710.0 -0.9487% MA 524.7 0.2982%
AAPL 229.98 0.7535% MSFT 429.03 1.0481% NVDA 137.71 3.0995% GOOGL 196.0 1.6018% GOOG 197.55 1.6151% AMZN 225.94 2.3928% META 612.77 0.2405% AVGO 237.44 3.5003% TSLA 426.5 3.0641% TSM 211.5 -1.5317% LLY 725.72 -4.208% V 319.62 0.747% JPM 259.16 1.9232% UNH 509.76 -0.1626% NVO 78.69 -5.2727% WMT 91.94 0.701% LVMUY 142.08 -1.4497% XOM 112.32 0.8983% LVMHF 710.0 -0.9487% MA 524.7 0.2982%

Singular Genomics Systems Inc

Healthcare US OMIC

19.7USD
-(-%)

Last update at 2025-01-17T14:30:00Z

Day Range

19.7019.70
LowHigh

52 Week Range

0.311.06
LowHigh

Fundamentals

  • Previous Close 19.70
  • Market Cap28.23M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-97.39100M
  • Revenue TTM2.91M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM -0.02400M
  • Diluted EPS TTM-1.31

Financials

Income Statement

2019-12-312020-12-312021-12-312022-12-31-90M-80M-70M-60M-50M-40M-30M-20M-10M0M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M50M100M150M200M250M300M350M
Total Assets
Total Liabilities

Change in Cash

2019-12-312020-12-312021-12-312022-12-31-120M-100M-80M-60M-40M-20M0M20M40M60M80M100M120M140M160M180M

Total Operating Cash

2019-12-312020-12-312021-12-312022-12-31-90M-80M-70M-60M-50M-40M-30M-20M-10M

Dividends Paid

2019-12-312020-12-312021-12-312022-12-310M0.5M1M1.5M2M2.5M3M3.5M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -90.87900M -98.77100M -27.94500M -12.32400M
Minority interest - - - -
Net income -88.27100M -98.88900M -28.66300M -12.34100M
Selling general administrative 47.26M 28.62M 6.29M 2.29M
Selling and marketing expenses - - - -
Gross profit -0.02400M - - -
Reconciled depreciation 6.03M 1.13M 0.64M 0.35M
Ebit -93.48700M -61.27900M -27.53400M -12.77000M
Ebitda -90.11600M -60.54600M -26.39000M -11.95700M
Depreciation and amortization 3.37M 0.73M 1.14M 0.81M
Non operating income net other 2.61M -1.44700M - -
Operating income -93.48700M -61.27900M -27.53400M -12.77000M
Other operating expenses 94.25M 61.28M 27.53M 12.77M
Interest expense 0.76M 0.85M 0.72M 0.02M
Tax provision - - - -
Interest income 3.37M 0.33M 0.51M 0.46M
Net interest income 2.61M -0.51800M -0.21300M 0.45M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -2.60800M 0.12M 0.72M 0.02M
Total revenue 0.77M 0.00000M 0.00000M 0.00000M
Total operating expenses 93.46M 61.28M 27.53M 12.77M
Cost of revenue 0.79M - - -
Total other income expense net 2.61M -37.49200M -0.41100M 0.45M
Discontinued operations - - - -
Net income from continuing ops -90.87900M -63.57200M -27.94500M -12.32400M
Net income applicable to common shares -90.87900M -98.77100M -27.94500M -12.32400M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 265.47M 327.98M 355.65M 30.50M 48.17M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.46M 4.72M 4.48M 0.65M 0.26M
Total liab 86.46M 67.65M 19.48M 82.06M 72.90M
Total stockholder equity 179.01M 260.32M 336.17M -51.55500M -24.72500M
Deferred long term liab - - - - -
Other current liab 1.86M 4.70M 4.40M 0.74M 0.55M
Common stock 0.00700M 0.00700M 0.00700M 0.00100M 0.00100M
Capital stock 0.00700M 0.00700M 0.00700M 0.00100M 0.00100M
Retained earnings -337.59500M -242.77500M -151.89600M -53.12500M -25.18000M
Other liab - 1.01M 2.83M 0.71M 0.17M
Good will - - - - -
Other assets - 2.86M 1.82M 0.56M 0.10M
Cash 16.23M 74.27M 201.05M 11.69M 5.50M
Cash and equivalents - - - - -
Total current liabilities 18.29M 14.12M 6.74M 3.69M 1.11M
Current deferred revenue 6.08M - - 1.59M -
Net debt 59.05M -15.42200M -191.14500M -2.29300M -3.10000M
Short term debt 7.76M 6.32M - 0.93M -
Short long term debt - - - 0.93M -
Short long term debt total 75.29M 58.84M 9.90M 9.39M 2.40M
Other stockholder equity 516.44M 503.93M 132.55M 1.55M 0.44M
Property plant equipment - 10.78M 6.07M 2.37M 1.61M
Total current assets 192.23M 268.43M 347.76M 27.57M 46.46M
Long term investments - - - - -
Net tangible assets - 260.32M 336.17M -51.55500M -24.72500M
Short term investments 157.71M 170.31M 138.17M 15.23M 40.70M
Net receivables 1.58M 0.91M 1.05M 0.02M -
Long term debt 8.90M 10.06M 9.90M 8.47M 2.40M
Inventory 13.57M 18.22M 3.01M - -
Accounts payable 2.59M 3.10M 2.35M 0.43M 0.56M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.15M -0.83700M -0.13800M 0.02M 0.01M
Additional paid in capital - - - - -
Common stock total equity - 0.00700M 0.00700M 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -242.77500M -151.89600M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.75M 2.86M 1.82M 0.56M 0.10M
Deferred long term asset charges - - - - -
Non current assets total 73.24M 59.54M 7.89M 2.93M 1.72M
Capital lease obligations 66.39M 48.78M - - -
Long term debt total - 10.06M 9.90M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -33.54400M -125.99700M 25.39M -30.70000M
Change to liabilities -1.00000M 2.30M -0.14800M 0.24M
Total cashflows from investing activities -39.56600M -130.86100M 24.00M -31.50000M
Net borrowings - 10.50M 7.50M 2.46M
Total cash from financing activities 0.90M 372.13M 7.51M 47.30M
Change to operating activities -1.24900M -4.76500M 1.01M 0.17M
Net income -90.87900M -98.77100M -27.94500M -12.32400M
Change in cash -125.75900M 189.57M 6.65M 4.41M
Begin period cash flow 201.74M 12.17M 5.52M 1.12M
End period cash flow 75.98M 201.74M 12.17M 5.52M
Total cash from operating activities -87.09400M -51.70100M -24.87300M -11.39900M
Issuance of capital stock 0.00000M 240.78M 0.05M 44.86M
Depreciation 6.03M 1.13M 0.64M 0.35M
Other cashflows from investing activities - - - -
Dividends paid - 3.58M - -
Change to inventory -13.48700M -13.48700M -13.48700M -13.48700M
Change to account receivables -0.91300M -0.91300M -0.91300M -0.91300M
Sale purchase of stock -0.45000M 3.58M -0.03000M -
Other cashflows from financing activities 1.18M 141.75M 7.50M 47.26M
Change to netincome 13.73M 11.51M 1.34M 0.16M
Capital expenditures 6.02M 4.86M 1.38M 0.80M
Change receivables -0.91300M - - -
Cash flows other operating 2.18M 29.99M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -125.75900M 189.57M - -
Change in working capital -16.81700M -2.91100M 0.86M 0.41M
Stock based compensation 13.67M 9.23M 1.06M 0.17M
Other non cash items 0.90M 35.48M 0.23M -0.01000M
Free cash flow -93.11600M -56.56500M -26.25300M -12.19900M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
OMIC
Singular Genomics Systems Inc
- -% 19.70 - - 10.86 0.18 0.77
ISRG
Intuitive Surgical Inc
8.56 1.47% 592.64 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA
2.72 2.20% 126.09 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme
- -% 249.58 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company
1.08 0.46% 237.38 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

Profile

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables focusing on the single cell and spatial analysis markets. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

Singular Genomics Systems Inc

3010 Science Park Road, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Andrew Spaventa Founder, CEO, Pres & Chairperson of the Board 1985
Dr. David L. Barker Ph.D. Founder, Member of Scientific Advisory Board & Independent Director 1942
Ms. Daralyn Durie Gen. Counsel 1968
Dr. Eli N. Glezer Ph.D. Founder, Chief Scientific Officer & Chair of Scientific Advisory Board 1969
Mr. Dalen Meeter Sr. VP of Fin. & CFO 1978
Mr. Jorge Velarde Jr., MBA Sr. VP of Corp. Devel. & Strategy 1967
Mr. Jeff Bullard Head of Sales NA
Mr. Vincent Brancaccio Sr. VP of HR 1983
Mr. Andrew Spaventa Founder, CEO, President & Chairperson of the Board 1985
Mr. Dalen Meeter Chief Financial Officer 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.